Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Meiji Seika Is Latest To Kick Off Ustekinumab Phase III

Sees Positive Phase I Results For Stelara Biosimilar With Dong-A Socio Holdings

Executive Summary

Meiji Seika and Dong-A Socio Holdings have become the latest developers to announce the start of Phase III trials for an ustekinumab biosimilar rival to Stelara.

You may also be interested in...



Intas Picks Up Global Rights To Meiji And Dong-A’s Stelara Biosimilar

Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.

Samsung Bioepis Is Latest To Move Ustekinumab Into Phase III

Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.

Bio-Thera Kicks Off Phase III Trial For Stelara Rival

Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.

Related Content

Topics

UsernamePublicRestriction

Register

GB150938

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel